Adverse events from drug therapy for human immunodeficiency virus disease

American Journal of Medicine

Volumn 101, Issue 1, 1996, Pages 34-40

  Moore, Richard D ^a   Fortgang, Ilana ^a   Keruly, Jeanne ^a   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; PANCREATITIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SKIN DISEASE;

EID: 0030199251     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00077-0     Document Type: Article

References (34)

1. 1. Bartlett J. Medical Management of HIV Infection. Glenview, Illinois: Physicians and Scientists, 1994.
2. 2. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120:932-944.
3. 3. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reactions and human immunodeficiency virus disease. J Acquired Immune Defic Syndr. 1991;5:1237-1257.
4. 4. Lee BL, Safrin S. Interactions and toxicities of drugs used in HIV infection. Clin Infect Dis. 1992;14:773-779.
5. 5. Barditch-Crovo P, Chaisson RE. Adverse reactions to therapy for HIV infection. Em Med Clin N Am. 1995;13:133-146.
6. 6. Harb GE, Alldredge BK, Coleman R, Jacobson MA. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquired Immune Defic Syndr. 1993;6:919-926.
7. 7. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. NEJM. 1993;328:1670-1674.
8. 8. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in drug therapy for HIV disease in an urban community. NEJM. 1994;330:763-768.
9. 9. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of HIV disease. NEJM. 1995;333:751-756.
10. 10. Hennessy S, Strom BL, Berlin JA, Brennan PJ. Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV-infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med. 1995;10:380-386.
11. 11. Vella S, Giuliano M, Dally LG, et al. Long-term follow-up of zidovudine therapy in asymptomatic HIV infection: results of a multicenter study. J Acquired Immune Defic Syndr. 1994;7:31-38.
12. 12. Schindzierlorz A, Pike I, Daniels M, et al. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis. 1994;19:1076-1083.
13. 13. Torres RA, Barr MR, McIntyre KI, et al. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease. Int J STD AIDS. 1995;6:19-26.
14. 14. Swanson CE, Tindall B, Cooper DA, and the Australian Zidovudine Study Group. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. AIDS. 1994;8:625-634.
15. 15. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprimsulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495-499.
16. 16. Moore RD, Keruly JC, Link GA, et al. Long-term safety and efficacy of zidovudine in patients with advanced HIV-disease. Arch Intern Med. 1991;151:981-985.
17. 17. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine: follow-up of patients in a compassionate plea program. JAMA. 1988;260:3009-3015.
18. 18. Hazel B, Sethi N, Jacquette G, et al. Diminished sulfamethoxazole-trimethoprim toxicity in blacks treated for PCP. Abstract F.3.2. V International Conference on AIDS, 1989, Montreal, Canada.
19. 19. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In Davies DM, ed. Textbook of Adverse Drug Reactions. London: Oxford University Press; 1977:44.
20. 20. Lilienfeld AM, Lilienfeld DE. Foundations of Epidemiology. 2nd ed. London: Oxford University Press; 1980.
21. 21. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. NEJM. 1987;317:192-197.
22. 22. Fischl MA, Richman DD, Grieco MH, et al. The safety and efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. NEJM. 1987;317:185-191.
23. 23. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med. 1990;112:727-737.
24. 24. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. NEJM. 1990;322:941-949.
25. 25. Fischl MA, Parker CR, Pettinelli C, et al. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. NEJM. 1990;322:1009-1014.
26. 26. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 1995;122:24-32.
27. 27. Schindzielorz A, Pike I, Daniels M, et al. Rates and risk factors for adverse events associated with didanosine in the expanded access program. Clin Infect Dis. 1994;19:1076-1083.
28. 28. Carr A, Swanson C, Penny R, Cooper DA. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis. 1993;167:180-185.
29. 29. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. NEJM. 1994;330:657-662.
30. 30. Colebunders R, Izaley L, Bila K, et al. Cutaneous reactions to trimethoprimsulfamethoxazole in African patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1987;107:599-600.
31. 31. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprimsulfamethoxazole in patients with acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:495-499.
32. 32. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-671.
33. 33. Van Der Ven AJ, Koopmans PP, Vree TB, Van Der Meer JWM. Adverse reactions to cotrimoxazole in HIV infection. Lancet. 1991;338:431-433.
34. 34. Carr A, Gross AS, Hoskins JM, et al. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. AIDS. 1994;8:333-337.